NeuroSphere is the McGill platform dedicated to innovation and partnership in neuroscience research and is funded through Healthy Brains, Healthy Lives (HBHL).
The aim of NeuroSphere is to address typical impediments to innovation, including:
- A lack of interest on the part of industry in high-risk, early-stage projects
- Academic results that often do not address industry concerns
- Absence or limited access to proof-of-concept and gap funding to allow early tech maturation
- Lack of end-user input needed to provide guidance for applicability
- Lack of uptake by the health-care system and policymakers
Through support from HBHL, McGill has an opportunity to focus on neuro-innovation and help high potential projects move towards commercialization.
The maturation and the acceleration of neuro-innovations developed at McGill University ultimately requires the creation of a dynamic entrepreneurship ecosystem in neuroscience and neuro-informatics. Strategic approaches and activities will also be undertaken to ensure NeuroSphere will act as facilitator for all commercialization projects coming out of the neuroscience community at McGill University.
Associate Director, Business Development
xavier.linker [at] mcgill.ca
Tel.: (514) 267-4135
Tel: (514) 398-4400 ext. 00064
Xavier Linker graduated from the Toulouse National Institute of Applied Sciences with a Diplôme d'Ingénieur (Master of Science in Engineering) in Biochemistry, and from the Toulouse Business School with a Specialized Master's degree in Biotechnology Management. Xavier joins HBHL with 14 years experience in Business Development, first in France and, since 2012, in Canada. He has held leadership positions in the biotech industry, including with Charles River Laboratories, Biospective (preclinical Contract Research Organizations) and Lallemand Health Solutions (manufacturer of probiotic strains).
laura.rivest-khan [at] mcgill.ca
Tel: (514) 398-4400 ext. 00064
Before joining HBHL, Laura Rivest-Khan worked at KisoJi Biotechnology as a Senior Research Associate and Project Leader while completing a Master of Business Administration, Sciences and Engineering from École des Sciences de la Gestion, UQAM. Prior to this, Laura worked at the Institute for Research in Immunology and Cancer at the University of Montreal. Laura holds a Master of Science in Molecular Biology, a Bachelor of Science in Biomedical Sciences, both from the University of Montreal, and completed a Double DEC Program in Science & Music (piano).
Entrepreneur in Residence
Marc Lussier, Ph.D.
marc.lussier3 [at] mail.mcgill.ca
Marc Lussier has recognized expertise in strategic planning, fundraising, finance, operations and human resources management with more than 15 years of experience in the biopharma sector. He has a proven track record in identifying investment opportunities and actively working with inventors, academic institutions, companies, investors and strategic partners to maximize the value of technologies through public and private financing. Dr. Lussier holds a Ph.D. in Molecular Biology. In 1998, he founded Mycota Biosciences Inc., a company developing new antifungal agents where he was Director of Scientific Operations until 2001. From 2002 to 2005, he was Vice President of Operations of HemaX Génome Inc, and CEO of Estracure Inc. He subsequently held several concurrent positions as Scientific Director of Procure Prostate Cancer Biobank; part-time Executive Director of Strida Pharma Inc.; Director of Business Development of Émerillon Therapeutics Inc; President and CEO of Florisys Inc.; and Portfolio Director of AgeChem Financial Inc. In 2008, Dr. Lussier became Director of Operations and Business Development of Hôpital Maisonneuve-Rosemont’s Centre of Excellence in Cell Therapy where he oversaw the center’s construction and operationalization.